Peter F. Zipfel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter F. Zipfel has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
C. Skerka
4 shared publicationsC Skerka
3 shared publicationsAlexandra Bialonski
Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, D-20359 Hamburg, Germany Tel.: +49-40-31182-472; Fax: +49-40-31182-400
2 shared publicationsChristine Skerka
2 shared publications- Jessica Caprioli
Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Via Camozzi 3, Ranica, Bergamo, Italy
2 shared publications - Marina Noris
Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
2 shared publications
Latest Publications
- 1 December 2013
- Published by Elsevier in Molecular Immunology
- Vol. 56 (3) , 282-283
Expression of recombinant ARMS2 and binding to self cell surfaces via glycosaminoglycans
- 1 December 2013
- Published by Elsevier in Molecular Immunology
- Vol. 56 (3) , 282-283
Expression of recombinant ARMS2 and binding to self cell surfaces via glycosaminoglycans
- 1 December 2013
- Published by Elsevier in Molecular Immunology
- Vol. 56 (3) , 243
CspA from Borrelia burgdorferi inhibits the terminal complement pathway
- 1 December 2013
- Published by Elsevier in Molecular Immunology
- Vol. 56 (3) , 243
CspA from Borrelia burgdorferi inhibits the terminal complement pathway
- 1 December 2013
- Published by Elsevier in Molecular Immunology
- Vol. 56 (3) , 314
Sequence variations and expression of the Candida albicans immune evasion proteins Gpm1 and Pra1 in clinical isolates contribute to virulence
- 1 December 2013
- Published by Elsevier in Molecular Immunology
- Vol. 56 (3) , 314
Sequence variations and expression of the Candida albicans immune evasion proteins Gpm1 and Pra1 in clinical isolates contribute to virulence
- 1 December 2013
- Published by Elsevier in Molecular Immunology
- Vol. 56 (3) , 250
Shiga toxin 2 binds and modulates complement regulatory proteins in the fluid phase and on host cell membranes
- 1 December 2013
- Published by Elsevier in Molecular Immunology
- Vol. 56 (3) , 250
Shiga toxin 2 binds and modulates complement regulatory proteins in the fluid phase and on host cell membranes
- 1 February 2001
- Vol. 12 (2) , 297-307
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.
The aim of the present study was to clarify whether factor H mutations were involved in genetic predisposition to hemolytic uremic syndrome, by performing linkage and mutation studies in a large number of patients from those referred to the Italian Registry for Recurrent and Familial HUS/TTP. PCR and Western blot analyses were conducted to characterize the biochemical consequences of the mutations. Five mutations in the factor H gene were identified. Three, identified in two families and in a sporadic case, are heterozygous point mutations within the most C-terminal short consensus repeat 20 (SCR20) of factor H, resulting in single amino acid substitutions. The other two mutations introduce premature stop codons that interrupt the translation of factor H. A heterozygous nonsense mutation was identified in SCR8 in one family, and a homozygous 24-bp deletion within SCR20 was identified in a Bedouin family with a recessive mode of inheritance. Reverse transcription-PCR analysis of cDNA from peripheral blood leukocytes from the Bedouin family showed that the deletion lowered factor H mRNA levels. Although heterozygous mutations were associated with normal factor H levels and incomplete penetrance of the disease, the homozygous mutation in the Bedouin family resulted in severe reduction of factor H levels accompanied by very early disease onset. These data provide compelling molecular evidence that genetically determined deficiencies in factor H are involved in both autosomal-dominant and autosomal-recessive hemolytic uremic syndrome and identify SCR20 as a hot spot for mutations in the disease. The mutations identified here give an important hint to the relevance of the C-terminus of factor H in the control of the alternative complement activation pathway.
- 1 February 2001
- Vol. 12 (2) , 297-307
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.
The aim of the present study was to clarify whether factor H mutations were involved in genetic predisposition to hemolytic uremic syndrome, by performing linkage and mutation studies in a large number of patients from those referred to the Italian Registry for Recurrent and Familial HUS/TTP. PCR and Western blot analyses were conducted to characterize the biochemical consequences of the mutations. Five mutations in the factor H gene were identified. Three, identified in two families and in a sporadic case, are heterozygous point mutations within the most C-terminal short consensus repeat 20 (SCR20) of factor H, resulting in single amino acid substitutions. The other two mutations introduce premature stop codons that interrupt the translation of factor H. A heterozygous nonsense mutation was identified in SCR8 in one family, and a homozygous 24-bp deletion within SCR20 was identified in a Bedouin family with a recessive mode of inheritance. Reverse transcription-PCR analysis of cDNA from peripheral blood leukocytes from the Bedouin family showed that the deletion lowered factor H mRNA levels. Although heterozygous mutations were associated with normal factor H levels and incomplete penetrance of the disease, the homozygous mutation in the Bedouin family resulted in severe reduction of factor H levels accompanied by very early disease onset. These data provide compelling molecular evidence that genetically determined deficiencies in factor H are involved in both autosomal-dominant and autosomal-recessive hemolytic uremic syndrome and identify SCR20 as a hot spot for mutations in the disease. The mutations identified here give an important hint to the relevance of the C-terminus of factor H in the control of the alternative complement activation pathway.
- 1 May 1999
- Published by Elsevier in Immunopharmacology
- Vol. 42 (1-3) , 53-60
The factor H protein family
- 1 May 1999
- Published by Elsevier in Immunopharmacology
- Vol. 42 (1-3) , 53-60
The factor H protein family
- 1 March 1999
- Published by Elsevier in Immunology Today
- Vol. 20 (3) , 135-140
FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function
- 1 March 1999
- Published by Elsevier in Immunology Today
- Vol. 20 (3) , 135-140
FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function
- 1 February 1999
- Vol. 10 (2) , 281-93
Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.
Familial hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) carry a very poor outcome and have been reported in association with decreased serum levels of the third complement component (C3). Uncontrolled consumption in the microcirculation, possibly related to genetically determined deficiency in factor H--a modulator of the alternative pathway of complement activation--may account for decreased C3 serum levels even during disease remission and may predispose to intravascular thrombosis. In a case-control study by multivariate analysis, we correlated putative predisposing conditions, including low C3 serum levels, with history of disease in 15 cases reporting one or more episodes of familial HUS and TTP, in 25 age- and gender-matched healthy controls and in 63 case-relatives and 56 control-relatives, respectively. The relationship between history of disease, low C3, and factor H abnormalities was investigated in all affected families and in 17 controls. Seventy-three percent of cases compared with 16% of controls (P < 0.001), and 24% of case-relatives compared with 5% of control-relatives (P = 0.005) had decreased C3 serum levels. At multivariate analysis, C3 serum level was the only parameter associated with the disease within affected families (P = 0.02) and in the overall study population (P = 0.01). Thus, subjects with decreased C3 serum levels had a relative risk of HUS or TTP of 16.56 (95% confidence interval [CI], 1.66 to 162.39) within families and of 27.77 (95% CI, 2.44 to 314.19) in the overall population, compared to subjects with normal serum levels. Factor H abnormalities were found in four of the cases, compared with three of the healthy family members (P = 0.02) and none of the controls (P = 0.04) and, within families, factor H abnormalities were correlated with C3 reduction (P < 0.05). Reduced C3 clusters in familial HUS and TTP is likely related to a genetically determined deficiency in factor H and may predispose to the disease. Its demonstration may help identify subjects at risk in affected families.
- 1 February 1999
- Vol. 10 (2) , 281-93
Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.
Familial hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) carry a very poor outcome and have been reported in association with decreased serum levels of the third complement component (C3). Uncontrolled consumption in the microcirculation, possibly related to genetically determined deficiency in factor H--a modulator of the alternative pathway of complement activation--may account for decreased C3 serum levels even during disease remission and may predispose to intravascular thrombosis. In a case-control study by multivariate analysis, we correlated putative predisposing conditions, including low C3 serum levels, with history of disease in 15 cases reporting one or more episodes of familial HUS and TTP, in 25 age- and gender-matched healthy controls and in 63 case-relatives and 56 control-relatives, respectively. The relationship between history of disease, low C3, and factor H abnormalities was investigated in all affected families and in 17 controls. Seventy-three percent of cases compared with 16% of controls (P < 0.001), and 24% of case-relatives compared with 5% of control-relatives (P = 0.005) had decreased C3 serum levels. At multivariate analysis, C3 serum level was the only parameter associated with the disease within affected families (P = 0.02) and in the overall study population (P = 0.01). Thus, subjects with decreased C3 serum levels had a relative risk of HUS or TTP of 16.56 (95% confidence interval [CI], 1.66 to 162.39) within families and of 27.77 (95% CI, 2.44 to 314.19) in the overall population, compared to subjects with normal serum levels. Factor H abnormalities were found in four of the cases, compared with three of the healthy family members (P = 0.02) and none of the controls (P = 0.04) and, within families, factor H abnormalities were correlated with C3 reduction (P < 0.05). Reduced C3 clusters in familial HUS and TTP is likely related to a genetically determined deficiency in factor H and may predispose to the disease. Its demonstration may help identify subjects at risk in affected families.
- Open Access
- 1 October 1998
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 273 (41) , 26923-26930
The Early Growth Response Protein (EGR-1) Regulates Interleukin-2 Transcription by Synergistic Interaction with the Nuclear Factor of Activated T Cells
- 1 October 1998
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 273 (41) , 26923-26930
Open AccessThe Early Growth Response Protein (EGR-1) Regulates Interleukin-2 Transcription by Synergistic Interaction with the Nuclear Factor of Activated T Cells
- 27 July 1998
- Published by Springer Nature in Parasitology Research
- Vol. 84 (8) , 623-631
The peroxidoxin 2 protein of the human parasite Onchocerca volvulus : recombinant expression, immunolocalization, and demonstration of homologous molecules in other species
The peroxidoxin protein of the filarial parasite Onchocerca volvulus (OvPXN-2) belongs to a group of highly conserved antioxidant molecules. For a more detailed characterization of this protein and for determination of its expression pattern the OvPXN-2 protein was recombinantly expressed as a His-tagged protein. Under reducing conditions the recombinant protein had an apparent molecular mass of 28 kDa. Considering the size of the His-tag and the FLAG epitope introduced to the recombinant protein, this size is in agreement with that of the native protein identified in O. volvulus extract. Antiserum raised against the recombinant protein was used for immunolocalization. In O. volvulus the antigen is predominantly expressed in the hypodermis and particularly the lateral and median chords show high levels of expression. The protein is also expressed strongly in the hypodermis of infective larvae and more weakly in microfilariae. Related cross-reacting proteins were detected in several Onchocerca species and other filariae. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis in combination with Western blotting revealed proteins with almost identical mobility in extracts prepared from O. ochengi, O. gibsoni, and Dirofilaria immitis.
- 27 July 1998
- Published by Springer Nature in Parasitology Research
- Vol. 84 (8) , 623-631
The peroxidoxin 2 protein of the human parasite Onchocerca volvulus : recombinant expression, immunolocalization, and demonstration of homologous molecules in other species
The peroxidoxin protein of the filarial parasite Onchocerca volvulus (OvPXN-2) belongs to a group of highly conserved antioxidant molecules. For a more detailed characterization of this protein and for determination of its expression pattern the OvPXN-2 protein was recombinantly expressed as a His-tagged protein. Under reducing conditions the recombinant protein had an apparent molecular mass of 28 kDa. Considering the size of the His-tag and the FLAG epitope introduced to the recombinant protein, this size is in agreement with that of the native protein identified in O. volvulus extract. Antiserum raised against the recombinant protein was used for immunolocalization. In O. volvulus the antigen is predominantly expressed in the hypodermis and particularly the lateral and median chords show high levels of expression. The protein is also expressed strongly in the hypodermis of infective larvae and more weakly in microfilariae. Related cross-reacting proteins were detected in several Onchocerca species and other filariae. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis in combination with Western blotting revealed proteins with almost identical mobility in extracts prepared from O. ochengi, O. gibsoni, and Dirofilaria immitis.